GlucoTrack Inc
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Stock Performance Snapshot
Financial Health
GlucoTrack Inc is producing steady cash flow but may need to improve profitability indicators.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GCTK
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Market Potential
The global diabetes-monitoring market is large and growing, which could support meaningful upside if devices gain clinical and regulatory acceptance, though outcomes are uncertain.
Regulatory Milestones
Approvals and clinical data are pivotal drivers of value; progress can boost sentiment but delays or negative results increase risk.
Partnering Pathways
Licences or partnerships with established medical-device firms could accelerate distribution and funding, but deals may dilute shareholders or change control dynamics.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
